Severe renal impairment has minimal impact on doravirine pharmacokinetics

Wendy Ankrom, Ka Lai Yee, Rosa I. Sanchez, Adedayo Adedoyin, Li Fan, Thomas Marbury, Richard A. Preston, Marian Iwamoto, Sauzanne G. Khalilieh

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

Doravirine is a novel nonnucleoside reverse transcriptase inhibitor in development for use with other antiretroviral therapies to treat human immunodeficiency virus type 1 (HIV-1) infection. Doravirine metabolism predominantly occurs via cytochrome P450 3A with 10% of elimination occurring via the renal pathway. As severe renal impairment can alter the pharmacokinetics (PK) of metabolically eliminated drugs, the effect of severe renal impairment on doravirine PK was assessed. A single dose of doravirine 100 mg was administered to subjects aged 18 to 75 years with an estimated glomerular filtration rate (eGFR) of 30 ml/min/1.73 m2 (severe renal impairment group) and healthy controls with an eGFR of 80 ml/min/1.73 m2, matched to the mean of the renal impairment group by age (10 years) and weight (10 kg). Doravirine plasma concentrations were determined at regular intervals, and safety was monitored throughout. The geometric mean ratios (90% confidence interval) for severe renal impairment/healthy subjects were 1.43 (1.00, 2.04), 1.38 (0.99, 1.92), and 0.83 (0.61, 1.15) for the plasma doravirine area under the curve from zero to infinity (AUC0–∞), plasma concentration at 24 h postdose (C24), and maximum plasma concentration (Cmax), respectively. Doravirine was generally well tolerated in both groups. Based on the overall efficacy, safety, and PK profile of doravirine, the minor effect of severe renal impairment on doravirine PK observed in this study is not considered clinically meaningful. (This study has been registered at ClinicalTrials.gov under identifier NCT02641067.)

Original languageEnglish (US)
Article numbere00326-18
JournalAntimicrobial agents and chemotherapy
Volume62
Issue number8
DOIs
StatePublished - Aug 2018

    Fingerprint

Keywords

  • Doravirine
  • HIV
  • Pharmacokinetics
  • Renal impairment

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Ankrom, W., Yee, K. L., Sanchez, R. I., Adedoyin, A., Fan, L., Marbury, T., Preston, R. A., Iwamoto, M., & Khalilieh, S. G. (2018). Severe renal impairment has minimal impact on doravirine pharmacokinetics. Antimicrobial agents and chemotherapy, 62(8), [e00326-18]. https://doi.org/10.1128/AAC.00326-18